← Return to Tumor growth in three month follow up MRI

Discussion

Tumor growth in three month follow up MRI

Neuroendocrine Tumors (NETs) | Last Active: 7 hours ago | Replies (6)
Comment receiving replies
@splendrous

Thanks for sharing. Do I understand that when you were diagnosed two years ago, you had surgery to remove the tumors with CT scans every 6 months as follow up. How large were your tumors at the time when they were removed? In 8/24 two years after the surgery a PET Dotatate was ordered because of what was seen in the CT and cancer was seen in the peritoneal.
How have your scans looked over the last 7 months you have been on Octreotide? Any change in the tumors? Where are you being treated? Thanks again.

Jump to this post

Replies to "Thanks for sharing. Do I understand that when you were diagnosed two years ago, you had..."
fraaseo | @fraaseo | 19 hours ago

@splendrous, my oncologist is located at the Springfield Clinic Cancer Center. My oncology surgeon is located in Naperville at Edward-Elmhurst Health Hospital. Both are fantastic!
Here is my history from beginning to current. Any questions, please ask!

DIAGNOSES:
1. Stage III (T3 N2 M0) well-differentiated neuroendocrine tumor of small bowel,
diagnosed in September 2022, 2.2 cm, grade 2, with 4 lymph nodes involved, status post
segmental resection in September 2022, Ki-67 score of 3-5%.
2. Recurrence of neuroendocrine tumor seen in July 2024 that showed peritoneal involvement, now stage IV disease. S/p peritoneal and omental resection, repeat small bowel, sigmoid colon, and liver segemental
resections performed October 1, 2024.
Pathology showed extensive involvement of the low-grade well-differentiated neuroendocrine tumor involving the peritoneum, liver, and lymph nodes.
TREATMENT:
Octreotide started October 29, 2024

P/o CT 3/2025
1. There is a new/worsening 1 x 1.7 cm enhancing ovoid focus of soft tissue in the right pelvis tethering the right superolateral vaginal fornix and right lateral wall of the cecum, concerning for metastatic disease.
2. New 1.3 cm soft tissue lesion in the deep subcutaneous fat of the left gluteal region, concerning for a metastatic implant. This may be amenable to
percutaneous biopsy via ultrasound. (This is from the Octreotide shot).
3. Evidence for colitis.
4. No evidence for metastatic disease in the chest.
5. Foci of tree-in-bud nodularity in the lungs are stable, possibly related to chronic atypical infection.

Continue Octreotide injections, follow up PET scan in 3 months.

VIEW AND REPLY